Open Payments

CARDIOLOGY PARTNERS CLINICAL

Type
Non-covered entity
Where
WELLINGTON, FL
Received
$957,434 in 30 records, 2019 to 2025 ($0 general, $957,434 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025Research payment8$313,624
2024Research payment6$140,386
2023Research payment4$74,986
2022Research payment4$200,668
2021Research payment4$200,298
2020Research payment2$2,229
2019Research payment2$25,242

By company

CompanyRecordsAmountYears
Eli Lilly and Company28$932,1922020–2025
E.R. Squibb & Sons, L.L.C.2$25,2422019

By nature of payment

NatureRecordsAmount
Research payment30$957,434

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-30Eli Lilly and Company$4,273Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2025
2025-12-16Eli Lilly and Company$2,447Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2025
2025-02-25Eli Lilly and Company$1,007Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2025
2025-02-25Eli Lilly and Company$219Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2025
2025-02-11Eli Lilly and Company$12,258Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2025
2025-01-27Eli Lilly and Company$10,116Research paymentIn-kind items and servicesA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2025
2025-01-21Eli Lilly and Company$113,480Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2025
2025-01-07Eli Lilly and Company$169,823Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2025
2024-08-27Eli Lilly and Company$3,427Research paymentIn-kind items and servicesA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2024
2024-08-20Eli Lilly and Company$49,888Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2024
2024-02-26Eli Lilly and Company$1,832Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2024
2024-01-17Eli Lilly and Company$3,934Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2024
2024-01-16Eli Lilly and Company$21,781Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2024
2024-01-02Eli Lilly and Company$59,522Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2024
2023-02-14Eli Lilly and Company$12,582Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2023
2023-01-26Eli Lilly and Company$2,287Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2023
2023-01-25Eli Lilly and Company$3,346Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2023
2023-01-03Eli Lilly and Company$56,771Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2023
2022-01-26Eli Lilly and Company$3,763Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2022
2022-01-26Eli Lilly and Company$1,421Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2022
2022-01-25Eli Lilly and Company$38,908Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2022
2022-01-04Eli Lilly and Company$156,576Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2022
2021-08-24Eli Lilly and Company$52,631Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2021
2021-06-15Eli Lilly and Company$135,628Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2021
2021-01-26Eli Lilly and Company$5,789Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2021
2021-01-25Eli Lilly and Company$6,249Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2021
2020-08-14Eli Lilly and Company$1,223Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2020
2020-08-14Eli Lilly and Company$1,005Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2020
2019-07-05E.R. Squibb & Sons, L.L.C.$12,471Research paymentCash or cash equivalentELIQUIS Drug, CardiovascularAn Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K A2019
2019-05-21E.R. Squibb & Sons, L.L.C.$12,770Research paymentCash or cash equivalentELIQUIS Drug, CardiovascularAn Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K A2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Palm Beach CountyWellington village

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Wellington, FL, county Palm Beach County, FL, state Florida; placed by its city name.

MeasurePlace (city or town)
Wellington, FL
County
Palm Beach County, FL
State
Florida
Population B0100362,1461,533,80622,416,077
Population, 2020 census P161,6371,492,19121,538,187
Median age B0100242.345.342.6
Under 18 B0100123.6%18.8%19.5%
65 and over B0100117.6%24.8%21.3%
Households B1100121,859605,4308,752,810
Foreign born B0500224.9%27.7%21.9%
Median household income B19013$115,632$83,581$74,568
Median family income B19113$135,150$102,287$89,891
Per capita income B19301$57,019$52,359$42,609
Poverty rate B170017.8%11.3%12.6%
Unemployment rate B230254.7%5.5%4.8%
Civilian labor force B2302531,702761,90011,016,578
Mean commute (minutes) B0801332.126.528.0
Bachelor's degree or higher B1500349.7%40.5%34.1%
Housing units B2500124,497719,46310,256,470
Owner-occupied B2500375.8%70.1%67.6%
Renters B2500324.2%29.9%32.4%
Median home value B25077$599,400$447,300$359,000
Median gross rent B25064$2,562$1,916$1,669
White, not Hispanic B0300250.8%49.6%50.4%
Black B0300212.1%18.1%14.6%
Hispanic or Latino B0300228.5%24.4%27.4%
Asian B030024.4%2.8%2.9%
American Indian and Alaska Native B030020.0%0.1%0.1%

Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); Unemployment rate: 4.9% in Sep 2016 to 4.4% in Sep 2026; low 2.8%, high 14.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Wellington, FL.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.